Avenzoar Pharmaceuticals announced it raised $900,000 in an initial filing from an offering of $2.97 Million

Company

Location

About

Avenzoar Pharmaceuticals is a start-up pharmaceutical company founded in 2016. Avenzoar is specialized in developing cancer drugs aiming at targeting and inhibiting mechanisms of metastasis and drug resistance. ​ Avenzoar has 3 drugs in the pipeline so far. The lead drug is AP-001 (aka Metavert), which is expected to be tested in pancreatic cancer patients in 2024/2025.